Cook Medical’s Ongoing Zilver® PTX® Trial Data Show Higher Freedom From Target Lesion Revascularization (TLR) Rates Compared to Angioplasty and Bare Metal Stenting After Three Years  
8/13/2012 9:41:10 AM

BLOOMINGTON, Ind.--(BUSINESS WIRE)--Previously unreleased three-year data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease indicate that Cook Medical’s paclitaxel-eluting peripheral vascular stent demonstrated 83.0 percent freedom from TLR at 36 months in the PTX group, compared to 70.2 percent for patients treated with optimal percutaneous transluminal angioplasty and bare metal stents in the 479 patient study.